CL2021001330A1 - Nuevos compuestos heterocíclicos - Google Patents
Nuevos compuestos heterocíclicosInfo
- Publication number
- CL2021001330A1 CL2021001330A1 CL2021001330A CL2021001330A CL2021001330A1 CL 2021001330 A1 CL2021001330 A1 CL 2021001330A1 CL 2021001330 A CL2021001330 A CL 2021001330A CL 2021001330 A CL2021001330 A CL 2021001330A CL 2021001330 A1 CL2021001330 A1 CL 2021001330A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic compounds
- compounds
- new heterocyclic
- new
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I): en donde A, B, L, X, R1, R2, R3 y R4 son, como se describen en la presente, composiciones que incluyen los compuestos, procesos para elaborar los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18207725 | 2018-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001330A1 true CL2021001330A1 (es) | 2021-10-29 |
Family
ID=64453331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001330A CL2021001330A1 (es) | 2018-11-22 | 2021-05-20 | Nuevos compuestos heterocíclicos |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20210387999A1 (es) |
| EP (1) | EP3883936B1 (es) |
| JP (1) | JP7444882B2 (es) |
| KR (1) | KR20210094540A (es) |
| CN (1) | CN113166170A (es) |
| AR (1) | AR117139A1 (es) |
| AU (1) | AU2019383500A1 (es) |
| BR (1) | BR112021009348A2 (es) |
| CA (1) | CA3119506A1 (es) |
| CL (1) | CL2021001330A1 (es) |
| CO (1) | CO2021007056A2 (es) |
| CR (1) | CR20210247A (es) |
| DK (1) | DK3883936T3 (es) |
| ES (1) | ES2955037T3 (es) |
| FI (1) | FI3883936T3 (es) |
| HR (1) | HRP20231083T1 (es) |
| HU (1) | HUE062913T2 (es) |
| IL (1) | IL283333B2 (es) |
| LT (1) | LT3883936T (es) |
| MA (1) | MA55131B1 (es) |
| MX (1) | MX2021005714A (es) |
| NZ (1) | NZ775640A (es) |
| PE (1) | PE20211870A1 (es) |
| PH (1) | PH12021551167A1 (es) |
| PL (1) | PL3883936T3 (es) |
| PT (1) | PT3883936T (es) |
| RS (1) | RS64579B1 (es) |
| SG (1) | SG11202104206SA (es) |
| SI (1) | SI3883936T1 (es) |
| TW (1) | TWI825227B (es) |
| UA (1) | UA128505C2 (es) |
| WO (1) | WO2020104494A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| JP7269948B2 (ja) | 2017-11-28 | 2023-05-09 | エフ． ホフマン－ラ ロシュ アーゲー | 新規複素環式化合物 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| UA127629C2 (uk) | 2018-08-13 | 2023-11-08 | Ф. Хоффманн-Ля Рош Аг | Нові гетероциклічні сполуки як інгібітори моноацилгліцеролліпази |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| US11814375B2 (en) | 2019-09-12 | 2023-11-14 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| BR112023003580A2 (pt) | 2020-09-03 | 2023-04-04 | Hoffmann La Roche | Compostos heterocíclicos |
| CN114195780A (zh) * | 2020-09-18 | 2022-03-18 | 上海医药集团股份有限公司 | 一种羰基杂环类化合物及其应用 |
| CN117177744A (zh) | 2021-01-29 | 2023-12-05 | 塞迪拉治疗股份有限公司 | Cdk2抑制剂及其使用方法 |
| TW202317560A (zh) | 2021-06-26 | 2023-05-01 | 美商賽迪拉治療股份有限公司 | Ｃｄｋ２抑制劑及其使用方法 |
| WO2023130050A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain |
| WO2023130043A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety |
| KR20240139073A (ko) * | 2022-01-25 | 2024-09-20 | 에프. 호프만-라 로슈 아게 | 신규 헤테로고리 화합물 |
| CN119301113A (zh) * | 2022-06-24 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的新的杂环羰基环状化合物 |
| AU2023322411A1 (en) | 2022-08-08 | 2024-11-21 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| WO2024033479A1 (en) * | 2022-08-11 | 2024-02-15 | Remynd N.V. | (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders |
| WO2024061853A1 (en) * | 2022-09-20 | 2024-03-28 | F. Hoffmann-La Roche Ag | Fluorescent probes for magl |
| WO2024088922A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| EP2475667A1 (en) | 2009-09-10 | 2012-07-18 | F. Hoffmann-La Roche AG | Inhibitors of jak |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| JP5990297B2 (ja) | 2015-03-03 | 2016-09-14 | タイヨーエレック株式会社 | 遊技機 |
| EP3279191B1 (en) * | 2015-03-30 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| MX2017014714A (es) | 2015-05-21 | 2018-01-25 | Glaxosmithkline Ip Dev Ltd | Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| ES2823049T3 (es) | 2015-07-31 | 2021-05-05 | Pfizer | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| WO2021048241A1 (en) * | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | Radiolabeled compounds |
-
2019
- 2019-11-20 CN CN201980077284.5A patent/CN113166170A/zh active Pending
- 2019-11-20 FI FIEP19809026.8T patent/FI3883936T3/fi active
- 2019-11-20 PL PL19809026.8T patent/PL3883936T3/pl unknown
- 2019-11-20 RS RS20230788A patent/RS64579B1/sr unknown
- 2019-11-20 LT LTEPPCT/EP2019/081870T patent/LT3883936T/lt unknown
- 2019-11-20 JP JP2021528972A patent/JP7444882B2/ja active Active
- 2019-11-20 KR KR1020217015287A patent/KR20210094540A/ko unknown
- 2019-11-20 AU AU2019383500A patent/AU2019383500A1/en active Pending
- 2019-11-20 PT PT198090268T patent/PT3883936T/pt unknown
- 2019-11-20 ES ES19809026T patent/ES2955037T3/es active Active
- 2019-11-20 HU HUE19809026A patent/HUE062913T2/hu unknown
- 2019-11-20 MX MX2021005714A patent/MX2021005714A/es unknown
- 2019-11-20 SG SG11202104206SA patent/SG11202104206SA/en unknown
- 2019-11-20 HR HRP20231083TT patent/HRP20231083T1/hr unknown
- 2019-11-20 WO PCT/EP2019/081870 patent/WO2020104494A1/en active Application Filing
- 2019-11-20 CR CR20210247A patent/CR20210247A/es unknown
- 2019-11-20 EP EP19809026.8A patent/EP3883936B1/en active Active
- 2019-11-20 CA CA3119506A patent/CA3119506A1/en active Pending
- 2019-11-20 BR BR112021009348-6A patent/BR112021009348A2/pt unknown
- 2019-11-20 NZ NZ775640A patent/NZ775640A/en unknown
- 2019-11-20 PE PE2021000714A patent/PE20211870A1/es unknown
- 2019-11-20 IL IL283333A patent/IL283333B2/en unknown
- 2019-11-20 DK DK19809026.8T patent/DK3883936T3/da active
- 2019-11-20 MA MA55131A patent/MA55131B1/fr unknown
- 2019-11-20 SI SI201930619T patent/SI3883936T1/sl unknown
- 2019-11-20 UA UAA202103201A patent/UA128505C2/uk unknown
- 2019-11-21 AR ARP190103417A patent/AR117139A1/es unknown
- 2019-11-21 TW TW108142267A patent/TWI825227B/zh active
-
2021
- 2021-05-20 US US17/325,934 patent/US20210387999A1/en active Pending
- 2021-05-20 CL CL2021001330A patent/CL2021001330A1/es unknown
- 2021-05-21 PH PH12021551167A patent/PH12021551167A1/en unknown
- 2021-05-28 CO CONC2021/0007056A patent/CO2021007056A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| CO2020009567A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) de oxazina | |
| DOP2017000267A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
| UY37487A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| CO2023016204A2 (es) | Inhibidores de nlrp3 | |
| CO2022002339A2 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| MX2022003023A (es) | Compuestos heterociclicos. | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 | |
| UY38943A (es) | Nuevas heteroaril piperidiniletanonas sustituidas de 6 miembros | |
| UY38749A (es) | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas | |
| BR112013028368A2 (pt) | novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona | |
| CL2021000486A1 (es) | Derivados de heteroarilo bicíclicos |